TORONTO, ON, CANADA (July 24, 2017)- Cyclica Inc. is pleased to announce that it has added Dr. Andy Hope as VP of Sales and Business Development.
Andy brings to Cyclica a rich background and over 25 years experience in sales and business development in the life sciences industry providing complex solutions and services to pharmaceutical and biotech companies. After obtaining his PhD in Chemistry from University College London (UCL), Andy spent his first ten years with two pioneers in the field of Computer Aided Molecular Design: Chemical Design and Biosym Technologies (both companies eventually became part of Accelrys, now known as Biovia). After a further seven years at Aspen Technology he then assumed increasing levels of responsibility at companies including Director of Business Development at GeneFormatics, Solutions Executive at IBM Healthcare and Life Sciences, Director of Business Development at GeneGo (Systems Biology), Director of Discovery & Translational Science at Thomson Reuters, and most recently Senior Director, Business Development and Strategic Alliances at Bio-ReferenceLabs/GeneDx.
Naheed Kurji, Cyclica’s President and CEO, had this to say, “Andy has a rich background in the industry, and will add demonstrable value to our strategic thinking, and global commercial endeavors. We are fortunate and thrilled to have his level of expertise at the management level leading our sales and business development efforts. I’m looking forward to working with Andy and the entire BD team to introduce Cyclica’s platform on the global stage.”
Andy had this to say about his appointment, “After spending over 20 years of my career selling a range of in silico solutions and services to pharmaceutical companies, I believe that Cyclica is well positioned to enable pharma R&D to capture significant value in drug discovery using its unique platform for structure based screening on a proteome wide scale, Ligand Express™. I am equally excited about the company's forward thinking innovative efforts. Cyclica delivers Ligand Express™ in a cloud-based platform that not only provides the scalable compute power required to perform these intensive analyses but also relieves pharmaceutical companies of the administrative overhead and burden of supporting a platform in-house. ”
— 30 —
Cyclica Inc. has developed, validated and patented a structure-based proteome-wide screening platform, Ligand Express™, that currently features PROBEx (proteome-screening), SWITCHx (ligand effect prediction) and DIVEx (systems biology & drug-protein interactomes). Ligand Express™ is unique in that it is a drug-centric platform. For a small molecule ligand, Ligand Express™ automatically generates an intelligent list of ligand-protein interactions by searching through a large proprietary database of all available structurally-characterized proteins. The platform provides a panoramic view of a small molecule ligand to better understand on- and off-target interactions, and is valuable in finding novel desirable or undesirable targets. By gaining insights into a ligand’s polypharmacology, Cyclica’s clients can identify unknown targets, prioritize lead candidates, elucidate adverse effects, and understand repurposing opportunities. www.cyclicarx.com